Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Crinetics Pharmaceuticals Inc

Healthcare US CRNX

33.09USD
0.48(1.47%)

Last update at 2026-06-03T20:00:00Z

Day Range

32.5033.59
LowHigh

52 Week Range

15.7653.70
LowHigh

Fundamentals

  • Previous Close 32.61
  • Market Cap3695.36M
  • Volume857614
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-246.87000M
  • Revenue TTM1.97M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM -125.48800M
  • Diluted EPS TTM-3.72

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -163.91800M -107.64100M -73.81200M -50.42200M -27.11500M
Minority interest - - - - -
Net income -159.95400M -106.71900M -72.86400M -49.53500M -27.11500M
Selling general administrative 42.39M 24.52M 18.03M 13.52M 6.66M
Selling and marketing expenses - - - - -
Gross profit 4.74M 1.08M 0.07M 1.19M 2.43M
Reconciled depreciation 0.98M 0.92M 0.95M 0.89M 0.47M
Ebit -168.86500M -108.62400M -75.90100M -54.71900M -29.18100M
Ebitda -167.88200M -107.70200M -74.95300M -53.83200M -28.71000M
Depreciation and amortization 0.98M 0.92M 0.95M 0.89M 0.47M
Non operating income net other - - 1.14M 3.41M 1.59M
Operating income -167.88200M -107.70200M -74.95300M -53.83200M -28.71000M
Other operating expenses 172.62M 108.78M 74.95M 53.83M 28.71M
Interest expense 4.32M 0.06M 0.99M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 4.32M 0.16M 0.99M 3.46M 1.75M
Net interest income 4.32M 0.16M 0.99M 3.46M 1.75M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.96400M -0.92200M -0.94800M -0.88700M 1.59M
Total revenue 4.74M 1.08M 0.07M 1.19M 2.43M
Total operating expenses 172.62M 108.78M 74.95M 53.83M 28.71M
Cost of revenue - - - 41.51M 24.48M
Total other income expense net 3.96M 0.06M 1.14M 3.41M 1.59M
Discontinued operations - - - - -
Net income from continuing ops -163.91800M -107.64100M -73.81200M -50.42200M -27.11500M
Net income applicable to common shares -163.91800M -107.64100M -73.81200M -50.42200M -27.11500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 635.35M 352.18M 351.01M 183.44M 130.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.25M 8.33M 0.91M 6.61M 4.95M
Total liab 96.25M 35.85M 19.07M 14.53M 13.24M
Total stockholder equity 539.11M -439.17300M -275.25500M -167.61400M -93.80200M
Deferred long term liab - - - 0.02M 0.05M
Other current liab 31.16M 18.60M 7.53M 4.90M 2.84M
Common stock 1191.83M 759.43M 607.58M 336.51M 210.79M
Capital stock 1191.83M 759.43M 607.58M 336.51M 210.79M
Retained earnings -653.70200M -439.17300M -275.25500M -167.61400M -93.80200M
Other liab - 6.10M 0.00200M 0.02M 0.05M
Good will - - - - -
Other assets 0.00000M 2.01M 0.57M 2.77M 0.58M
Cash 54.90M 32.67M 200.69M 93.09M 40.33M
Cash and equivalents - - - - -
Total current liabilities 43.94M 27.72M 15.99M 10.49M 8.34M
Current deferred revenue 2.06M 2.24M - - -
Net debt -3.16900M -30.64800M -197.62100M -89.07300M -35.47700M
Short term debt 4.17M - - 4.01M -
Short long term debt - - - - -
Short long term debt total 51.73M 2.02M 3.07M 4.01M 4.85M
Other stockholder equity - -755.50100M -607.19900M -336.53300M -210.94100M
Property plant equipment - 4.99M 4.72M 5.41M 6.46M
Total current assets 574.15M 345.18M 344.72M 177.49M 123.34M
Long term investments 0.47M 0.00000M 1.01M - -
Net tangible assets - 316.33M 331.94M 168.92M 117.14M
Short term investments 503.66M 301.75M 133.01M 77.79M 78.07M
Net receivables 9.35M 2.42M 2.03M 1.83M 1.38M
Long term debt - - - - -
Inventory - - 8.07M -1.83300M -1.37800M
Accounts payable 6.55M 6.88M 8.47M 5.59M 5.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.98M -3.93100M -0.38200M 0.03M 0.15M
Additional paid in capital - - - - -
Common stock total equity - - - 336.51M 210.79M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -167.61400M -93.80200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.00M 2.01M 0.57M 0.54M 0.58M
Deferred long term asset charges - - - - -
Non current assets total 61.20M 6.99M 6.29M 5.95M 7.04M
Capital lease obligations 51.73M 2.02M 3.07M 4.01M 4.85M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -173.98000M -56.48300M 0.22M 42.16M -118.39900M
Change to liabilities 19.34M 6.29M 2.72M 0.70M 7.36M
Total cashflows from investing activities -173.98000M -56.48300M 0.22M 41.67M -119.45800M
Net borrowings - - - - -
Total cash from financing activities 121.96M 252.68M 114.57M 0.07M 170.20M
Change to operating activities -0.72300M -5.19700M -2.34700M -2.82900M -2.06300M
Net income -163.91800M -107.64100M -73.81200M -50.42200M -27.11500M
Change in cash -167.22200M 107.61M 52.76M -4.64700M 31.28M
Begin period cash flow 201.19M 93.59M 40.83M 45.47M 14.19M
End period cash flow 33.97M 201.19M 93.59M 40.83M 45.47M
Total cash from operating activities -115.20500M -88.58800M -62.02700M -46.38100M -19.45900M
Issuance of capital stock 117.24M 249.54M 114.28M 0.00000M 169.75M
Depreciation 0.98M 0.92M 0.95M 0.89M 0.47M
Other cashflows from investing activities - - - 42.16M -118.39900M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 10.99M - - - -
Sale purchase of stock - 0.00000M 114.57M -0.05900M 170.20M
Other cashflows from financing activities 4.72M 3.14M 0.29M 0.13M 63.73M
Change to netincome 29.12M 17.04M 10.46M 6.29M 1.89M
Capital expenditures 1.66M 0.44M 0.19M 0.49M 1.06M
Change receivables - - - - -
Cash flows other operating - - -2.06900M -2.60300M -2.06300M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 52.76M -4.64700M 31.28M
Change in working capital 18.61M 1.10M 0.38M -2.13300M 5.30M
Stock based compensation 28.27M 17.35M 10.43M 6.29M 2.32M
Other non cash items 0.85M -0.73900M 0.26M 0.22M -0.43300M
Free cash flow -116.86100M -89.02400M -62.21300M -46.87300M -20.51800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRNX
Crinetics Pharmaceuticals Inc		 0.48 1.47% 33.09 - - 865.90 6.45 739.61 -13.3992
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals Inc

6055 Lusk Boulevard, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. R. Scott Struthers Ph.D. Founder, Pres, CEO & Director 1962
Mr. Jeff E. Knight Chief Operating Officer 1971
Dr. Stephen F. Betz Ph.D. Founder & Chief Scientific Officer 1966
Mr. Marc J. C. Wilson Chief Financial Officer 1979
Ms. Garlan Adams Gen. Counsel & Corp. Sec. NA
Ms. Adriana Cabre M.B.A. Chief HR Officer NA
Dr. Alan S. Krasner M.D. Chief Medical Officer 1963
Mr. Kevin Capps Head of Intellectual Property NA
Mr. James Hassard Chief Commercial Officer 1966
Mr. Chris Robillard M.B.A. Chief Bus. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions